Age-Related Eye Disease Follow-up Study (AREDS) Follow-up Study

105名以前在急性呼吸窘迫综合征临床中心登记的参与者将在五年内每年接受跟踪调查。这些年度检查将包括全面的视力检查、眼底和晶状体照片以及血样。此外，临床协调员将每半年向参与者进行一次电话交流。这些后续访问将提供一组参与者的数据，我们将拥有非常不同寻常的能力来报告两种疾病--白内障和AMD--的15-18年自然病史。它还将提供与AREDS补充剂(高剂量维生素C、E、β-胡萝卜素、锌和铜)治疗相关的可能不良反应的更多数据。文献中有关于AMD在15年期间进展的个别病例报告，以及关于参与者队列随访10年的人口数据，但据我们所知，在15年期间没有收集到系统的数据。基于人群的数据显示，80岁以后AMD进展的风险明显增加。通过系列照片在很长一段时间内跟踪疾病的发展，这将使我们能够更好地提出假设，解释为什么有些人会进步，而另一些人则不会。 研究目标 这项研究的目的是对105名前AREDS参与者进行为期5年的跟踪调查，每半年一次电话联系，以收集有关AMD和白内障的额外数据。这些后续访问将使NEI能够收集有关AMD和白内障可能发生的眼部事件的更多数据，并记录与AREDS治疗相关的任何不良反应。最重要的是，这种对白内障和AMD进展的仔细摄影记录的非常长的随访将允许开发为什么有些人进步而另一些人不进步的假说。

One-hundred and five participants previously enrolled at the Clinical Center for AREDS will be followed on an annual basis for five years. These annual visits will include a comprehensive eye exam, fundus and lens photographs and a blood sample. In addition, clinical coordinators will conduct semi-annual phone calls to the participants. These follow-up visits will provide data on a cohort of participants for whom we will have the very unusual ability to report on the 15-18 year natural history of two diseases, cataract and AMD. It will also provide additional data on possible adverse effects associated with the treatment with AREDS supplements (high doses of vitamins C, E, beta-carotene, zinc and copper). There are individual case reports in the literature on the progression of AMD over a 15-year period, and population data on follow-up of cohorts of participants for 10 years, but to our knowledge no systematic data have been collected over a 15-year period. The population based data demonstrate a clear increase in the risk of AMD progression after age 80. The ability to follow this progression of disease over a very long period with serial photos will allow us to better develop hypotheses as to why some persons progress while others do not. Study Objectives The objective of this study is to follow 105 former AREDS participants annually for 5 years with a semi-annual telephone contact to collect additional data on AMD and cataracts. These follow-up visits will allow the NEI to collect additional data on possible ocular events for both AMD and cataracts and for documentation of any adverse effects associated with the AREDS treatment. Most importantly, this very long follow-up with careful photographic documentation of the progress of both cataract and AMD will allow for the development of hypotheses as to why some persons progress while others do not.